Estrella Immunopharma Inc (NASDAQ:ESLA) stock tumbled 8.6% on Monday after the clinical-stage biopharmaceutical company announced it had entered into definitive agreements for an $8 million registered direct offering and concurrent private placement.<\/p>\n
The offering, priced at-the-market under Nasdaq rules, consists of 5,063,290 units priced at $1.58 each, with each unit containing one share of common stock or one pre-funded warrant, plus one and a half investor warrants. The investor warrants are exercisable at $1.39 per share.<\/p>\n
The transaction involves a single healthcare-focused institutional investor and is expected to close around January 6, 2026, subject to customary closing conditions. Aegis Capital Corp is acting as the exclusive placement agent for the offerings.<\/p>\n
Estrella Immunopharma, which develops CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, intends to use the proceeds for general corporate purposes and working capital.<\/p>\n
The company\u2019s stock decline reflects typical market reaction to equity offerings that can potentially dilute existing shareholders. The pre-funded warrants included in the offering are immediately exercisable at an exercise price of $0.00001, while the investor warrants have an exercise price of $1.39 per share.<\/p>\n","protected":false},"excerpt":{"rendered":"
Estrella Immunopharma Inc (NASDAQ:ESLA) stock tumbled 8.6% on Monday after the clinical-stage biopharmaceutical company announced it had entered into definitive agreements for an $8 million registered direct offering and concurrent private placement. The offering, priced at-the-market under Nasdaq rules, consists of 5,063,290 units priced at $1.58 each, with each unit containing one share of common […]<\/p>\n","protected":false},"author":2,"featured_media":1449,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-1448","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.nimbushubconsulting.com\/index.php?rest_route=\/wp\/v2\/posts\/1448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nimbushubconsulting.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nimbushubconsulting.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nimbushubconsulting.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nimbushubconsulting.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1448"}],"version-history":[{"count":1,"href":"https:\/\/www.nimbushubconsulting.com\/index.php?rest_route=\/wp\/v2\/posts\/1448\/revisions"}],"predecessor-version":[{"id":1450,"href":"https:\/\/www.nimbushubconsulting.com\/index.php?rest_route=\/wp\/v2\/posts\/1448\/revisions\/1450"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nimbushubconsulting.com\/index.php?rest_route=\/wp\/v2\/media\/1449"}],"wp:attachment":[{"href":"https:\/\/www.nimbushubconsulting.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nimbushubconsulting.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nimbushubconsulting.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}